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Title: An open-label, randomised, multicentre crossover trial assessing two-layer 
compression therapy bandaging (AndoFlex® TLC Calamine versus Coban2®) in chronic 
venous insufficiency patients; results of the APRICOT trial. 
Abstract  
Background Compression bandaging is the mainstay therapy for chronic venous 
insufficiency and venous leg ulcers, but patient compliance can be challenging due to 
associated discomfort. 
Aims Comparison of AndoFlex® TLC Calamine versus Coban2® compression bandaging in 
relation to patient comfort and related pruritus symptomology, with severity of pruritus 
scale as primary outcome. 
Methods  Multi-centre, prospective, non-blinded, randomised controlled crossover trial 
involving 39 randomised participants. Two periods for chronic venous insufficiency patients, 
to wear either AndoFlex® TLC Calamine or Coban2® for three weeks each.  
Findings No significant differences in validated pruritus outcome measures were observed, 
including a non-significant treatment effect for the severity of pruritus scale (n = 35 trial 
completers, p-value 0.24, Wilcoxon test). However, after trying both bandages, 21 out of 35 
patients (60%) definitely preferred AndoFlex® TLC Calamine whereas 4 patients (11%) 
definitely preferred Coban2®.  
Conclusion AndoFlex® TLC Calamine compression bandage therapy is preferred by the 
majority of patients, although this observation could not be confirmed using validated 
patient-reported outcome measures for pruritus. Further research is indicated to establish if 
patient preference translates into favourable clinical outcomes.  
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Background 
Chronic venous insufficiency (CVI) is associated with a host of different conditions, ranging 
from varicose veins to venous leg ulcers (VLU).  It is well-established that a ‘Western’ 
lifestyle of obesity and lack of exercise increases the risk of CVI; in the USA, for example, it is 
the seventh leading cause of disability (Danielsson et al, 2002; White, 1993). Similar high 
incidences are found in Europe, with a prevalence of varicose veins occurring in more than 
10% of adults in Scotland (Bergan et al, 2006). VLUs are the most common type of leg ulcers, 
affecting 1-3% of the population over 60 years and this incidence is expected to increase 
with an ageing population (SIGN, 2010; Graham et al, 2003). Each year, the NHS spends 
approximately £2.3bn – £3.1bn (at 2005-2006 cost) on dressings and associated products, 
equating to 3% of the total estimated health expenditure (Posnett and Franks, 2008). 
Furthermore, patients with wounds cost the NHS up to £5 billion more per annum than 
matched control patients (Guest et al, 2015).  
 
The mainstay of treatment of VLUs is the reversal of venous hypertension through 
compression bandaging, to be followed by intervention to treat the venous reflux (O’Brien 
et al, 2012). However up to 15-30% do not respond to this current gold standard treatment 
and remain unhealed even after 6 months of treatment (O’Meara et al, 2009; Moffatt et al, 
2006). Treatment success in CVI is highly dependent on achieving high levels of patient 
compliance. Unfortunately, compliance rates are often poor in this population (Heinen et al, 
2007). Minimising the frequency of undesirable effects related to compression bandaging 
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may make the therapy more comfortable. Apart from bandage slippage, the most common 
undesirable effects of wearing compression bandaging are skin-related; pruritus develops in 
as many as 1 in 3 patients and can be a reason for non-compliance in 1 in 5 patients (Ayala 
et al, 2019; Stansal et al, 2013; Reich-Schupke et al, 2009). Some decades ago, Unna’s boot 
was developed; this concerned a gauze dressing impregnated with calamine, a compound 
substance of primarily zinc oxide and less than one percent ferric oxide (Rubin et al, 1990). 
Technology has advanced and current compression bandaging products tend to be two-
layer short stretch compression bandaging systems (Hanna et al, 2008). Unna’s boot has 
been shown in the past to be effective at controlling pruritis in different conditions, 
including burns-related long-term itch (Shohrati et al, 2007). Recently, Andover Healthcare 
(part of Milliken & Company) has introduced a two-layer short stretch compression bandage 
that contains Calamine, though its performance in relation to other existing compression 
bandage products has not been appraised (Todd, 2019).  The aim of this randomised, 
controlled, crossover trial was to determine patient experience and preference concerning 
two types of two-layer compression bandaging, namely Andover Healthcare’s AndoFlex® 
TLC Calamine and 3M’s Coban2® system in a population of patients who require 
compression bandaging due to CVI, with severity of pruritus as the primary outcome.   
 
Methods 
Study design and patients 
The APRICOT pilot study (A Patient and clinician Reported Impression of COmpression 
Therapy study) is a multi-centre, prospective, controlled crossover trial of two types of 
compression bandaging therapy, involving patients deemed to benefit from this 
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intervention. Patients enrolled were from four NHS organisations in England; one vascular 
department in a hospital Trust and three GP practices. Full research governance clearance 
was obtained from the National Research Ethics Service (reference 18/WA/0383), Health 
Research Authority (reference 252438) and the NHS Trusts; the study was also registered on 
the International Standardised Clinical Trial Number registry under reference 
ISRCTN95282887. The crossover study design was opted for to measure the degree of 
itchiness caused by either of the compression bandage brands in the same patient, and to 
be able to measure patient preference. The premise of the study was not for each patient to 
commence with no pruritus present at all or to reduce a degree of pruritus to zero. A 
washout or non-compression period was not feasible for this patient population, but the risk 
of carry-over effect was minimised by having a 3-week trial period per compression bandage 
brand and then applying questionnaires that cover a shorter period. 
Eligibility criteria were patients with mental capacity and command of English who were 
aged 18 years or older, with a clinical diagnosis of chronic venous insufficiency and CEAP 
clinical score of C2 or higher (Eklof et al, 2004).  Additional exclusion criteria were limited 
life expectancy such as palliative care, history of not being able to tolerate compression, 
calamine or zinc oxide, and an ankle brachial pressure index (ABPI) of < 0.5. Written 
informed consent was obtained, and thereafter participants were allocated 1:1 at random 
to commence either Coban2® or AndoFlex® TLC Calamine first, using a non-restricted 
randomised sequence generated for the whole sample using a freeware randomisation 
programme called Randomizer.org. Sequential envelopes with each next randomisation 
allocation were used to achieve concealment – there was no block randomisation by 
recruiting centre. A member of the study team who did not see patients generated the 
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randomisation sequence, and clinical staff enrolled patients and assigned the participants to 
the interventions. Since the primary focus was symptomology and not wound healing, there 
was no prerequisite for patients to have an ulcer, and no stratification for ulcer size or 
chronicity took place. As the study involved compression bandages that looked different,  it 
was not possible to achieve blinding for the participants, clinical, or research staff.  
Intervention and outcomes 
At baseline (week 0), patients - who either newly required or were already prescribed leg 
compression bandaging - were allocated to wear one brand of compression bandage for 3 
weeks first (pre-crossover, i.e. up to week 3), followed by subsequently wearing the other 
second brand for 3 weeks (post-crossover, i.e. week 6). The standard choice of compression 
bandage outside the trial was Coban2®. Both ‘Lite’ (25-30 mmHg) and normal (35-40 mmHg) 
compression patients were invited to participate since they were administered the 
corresponding equivalent before and after crossover. Furthermore, Coban2® Lite and 
AndoFlex® TLC Calamine Lite, plus Coban2® and AndoFlex® TLC Calamine respectively, offer 
comparable compression. For all patients, current standard practice of applying emollient 
(Epaderm or Dermol in this study) before applying compression bandaging continued for all 
study participants and both pre- and post-crossover (Brown and Butcher, 2005). 
At weeks 0, 3, and 6, clinical and patient related outcome measures were recorded. Pruritus 
was measured through patient feedback using the Severity of Pruritus Scale (SPS) score 
(Yosipovitch et al, 2017), visual pruritus score (Reich et al, 2012), and the 5-D itch score 
(Elman et al, 2010). Wound size was determined with the Pressure Ulcer Scale for Healing 
(PUSH) score tool, which is also validated for use on venous leg ulcers (Ratliff and 
Rodeheaver, 2005). Patient-reported quality of life in relation to their vascular disease was 
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measured using the Chronic Venous dIsease quality of life Questionnaire (CIVIQ-20)  
(Launois et al, 2010). The Venous Clinical Severity Score (VCSS) was used by the clinical staff 
to report on status of the venous insufficiency and related symptomology (Vasquez et al, 
2010). Further patient feedback recorded included patient feedback on bandage comfort 
over the 3 weeks that it had been worn (including a survey list of symptoms, and severity if 
any of the symptoms experienced), plus patient preference concerning the two bandage 
brands at the end of the crossover trial when both brands had been worn. Any adverse 
events, withdrawal, lost to follow-up and VLU infection rates were also recorded. Serious 
adverse events were pre-defined in the protocol and the study was managed in accordance 
with good clinical practice. 
  
Statistical analysis 
Since pruritus has been reported as an undesirable effect by patients (Reich-Schupke et al, 
2009), and one of the compression bandages in the trial contains Calamine with the aim to 
control this feature, this was used for a priori sample size calculations. With no pilot data 
available, an hypothetical distribution of responses on the SPS was used for sample size 
calculation purposes. The estimated clinically important difference for SPS is 20% 
(Yosipovitch et al, 2017). A minimum of 25 patients needed to be enrolled to achieve 80% 
power, 5% significance, at 20% attrition rate and a slightly more pronounced 30% difference 
between mild and moderate symptoms between the two different bandages (at each 
respective time point), whilst applying the Chi-squared test. To allow comparative analysis 
of before and after crossover periods, a per protocol approach was applied. The Mann-
Whitney U-test was applied for the outcomes measures for individual time points, whereas 
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the Wilcoxon signed-rank test was used for paired analysis of combined week 3 and week 6 
outcome data. Carryover effect was calculated by performing Wilcoxon test on the sum 
average for the Andoflex® TLC Calamine first group versus the Coban2® first group. 
Treatment effect was assessed by performing Wilcoxon test on the difference between 
week 3 and week 6 outcomes for the Andoflex® TLC Calamine group, and the difference 
between week 6 and week 3 for the Coban2® first group (Koch, 1972). Analysis for period 
effect was not performed due to relatively short intervention periods. Data was collated 
using Excel software and analysed with SPSS v20. 
 
Results 
From February 2019 to and including November 2019, 61 patients were considered of which 
39 were randomised; data is presented in Figure 1. The vascular department enrolled 36 
patients, and each of the three GP practices recruited one patient; recruitment was ended 
since the planned target had been reached (it was exceeded due to presentation of more 
suitable patients than anticipated in planned enrolment period).  A total of 35 out of 39 
(90%) patients completed the 6-week two-phase trial period. A single adverse event 
occurred, where a patient had to be taken off AndoFlex® TLC Calamine due to a mild skin 
reaction which could probably be attributed to the bandage. In Table 1, an overview is given 
of baseline patient characteristics for each respective ‘first treatment’ randomisation arm 
and for the study cohort as a whole. Patients who first commenced on AndoFlex® TLC 
Calamine where on average younger, but otherwise the treatment arms were similar. All 
participants, bar one, were instructed to wear the compression bandaging continuously in 
line with clinical needs. Table 2 shows how the performance of AndoFlex® TLC Calamine 
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compared to Coban2® as measured using validated questionnaires. These include 
measurement of pruritus (SPS tool, visual pruritus score and 5D itch score), patient-reported 
quality of life in relation to their chronic venous insufficiency (CIVIQ20), clinician score of 
severity of the patient’s vascular disease (VCSS) and a semi-quantitative PUSH score on 
venous ulcer size. No significant carryover effect was observed for any of the outcome 
measures. The treatment effect observed for SPS was also non-significant at 0.24, and 
therefore no significant difference in pruritus levels was observed between the two 
compression bandage therapies. Similarly, no significant difference was observed for the 
other two validated pruritus measurement tools. In the case of the non-itchiness measures - 
ulcer size, venous disease symptoms and quality of life - a smaller score indicates a more 
favourable outcome.  . Table 2 shows that a significant treatment effect was observed for 
Andoflex® TLC Calamine versus Coban2® in relation to PUSH score and VCSS. This suggests 
that  Andoflex® TLC Calamine may be associated with accelerated improvement in clinical 
features of VLU. 
Non-validated surveys were administered to participants when compression bandage was 
applied for the first time and at the end of each three week period. The instant reaction 
surveys were non-informative since all patients reported positively about the comfort and 
fit of the bandaging, regardless of the applied brand. At the end of the trial period for each 
bandage, the participants were asked to report whether they experienced symptoms that 
may be associated with wearing compression bandaging, and what the frequency and 
severity of said symptom was whilst wearing each brand of compression bandaging 
(responses for each brand of compression bandaging from the pre- and post-crossover trial 
phases were merged). Of the 11 symptoms assessed, ‘pins and needles’ were almost never 
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experienced by any participant, sweating was a rare occurrence and there were no patient-
reported difficulties getting dressed with either bandage. Hardly any patients felt a degree 
of heaviness or burning sensation whilst wearing either compression bandage. Figures 2 and 
3 summarise the data for the remaining six symptoms that were investigated. The 
occurrence of symptoms is shown in Figure 2, whilst Figure 3 depicts the severity of these 
symptoms. Itchiness was confirmed as the most common symptom experienced by patients, 
followed by three other symptoms: a sensation of constriction; pain; and movement 
restriction. Patients experienced pruritus more often when wearing Coban2® and the 
symptoms were more troublesome. Coldness was a symptom experienced when wearing 
AndoFlex® TLC Calamine in particular, though the symptoms were deemed mild.   
To explore if there are any signs of impact on wound healing by either of the compression 
bandage brands, for all participants the PUSH score was recorded (score of nil for patients 
without an ulcer) at baseline, week 3 and week 6. Although the leg ulcers in the cohort that 
used AndoFlex® TLC Calamine first were on average significantly larger, this difference had 
reduced to a non-significant difference versus the Coban2® cohort by the end of week 3. 
However, when AndoFlex® TLC Calamine was used post-crossover, a no significant 
improvement versus Coban2® was observed both versus the other cohort within that 
timeframe and versus the pre-crossover period involving the same cohort of patients.  
Figure 4 summarises the responses by patients concerning their preference for any of the 
two compression bandage brands that they wore in the preceding six weeks. Q1-Q9 
corresponds to the nine questions in Table 3.  Overall, more patients preferred AndoFlex® 
TLC Calamine; from a patient point-of-view it appears that the degree of comfort offered by 
AndoFlex® TLC Calamine was the main reason to prefer it over Coban2® (Q3, Q5, and Q9), 
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with pruritus control being a secondary reason (Q5). Patients were also offered the chance 
to write additional comments about their experience with wearing the two compression 
bandages. The most common free-text patient comments associated with wearing 
AndoFlex® TLC Calamine were that it felt ‘cooling’ (mentioned six times) and ‘soothing’ 
(noted five times). These observations were not made by patients when they wore 
Coban2®. A total of five nurses applied both compression bandage brands to the trial 
participants’ legs. At the end of the trial they were asked whether they had a preference 
regarding the bandages. On a 5-point Likert scale, three nurses ‘probably’ preferred and two 
nurses ‘definitely’ preferred to use AndoFlex® TLC Calamine over Coban2®.  
Discussion 
Significant advances have been made in compression bandage technology, particularly with 
the progression from four-layer to two-layer designs. Unna’s boot is a four-layer 
compression bandage treatment option which has since been surpassed in popularity by 
two-layer short stretch designs due to the improved application, although their respective 
wound healing efficacy is similar (De Carvahlo et al, 2018; Ashby et al, 2014). AndoFlex® TLC 
Calamine revisits the use of calamine in Unna’s boot in the modern two-layer compression 
bandage design, and this study assessed patient feedback of said product versus the 
established Coban2® brand through a randomised crossover trial. This study shows that a) 
pruritus is the most common and most bothersome symptom associated with wearing 
compression bandaging and b) AndoFlex® TLC Calamine is preferred by patients for the 
degree of comfort provided, but no significant difference was observed in this study versus 
Coban2® when validated outcome measures for pruritus were applied.  
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AndoFlex® TLC Calamine was preferred over Coban2® by the majority of participants in this 
study, possibly due to the reduced itchiness and cooling/soothing effect reported by 
participants. A degree of carry-over effect, a known risk in crossover studies where there is 
no washout period possible (Mills et al, 2009), may have occurred since the carry-over p-
values for pruritus surveys were close to the significance level of 0.05. Although the 
difference in pruritus levels between the two bandage brands was less obvious according to 
the outcomes measured with validated scales for itchiness, the anti-pruritic effect of Unna’s 
boot has been demonstrated before in patients with sulphur mustard exposure.16 Zinc 
oxide, the main ingredient of calamine, is a recognised antipruritic agent and like calamine 
itself is applied for a multitude of disorders (Gupta et al, 2014; Mak et al, 2013). 
Impregnation of textiles with zinc oxide, akin to the AndoFlex® TLC Calamine approach, is an 
emerging therapy modality for e.g. atopic dermatitis (Wiegand et al, 2013). In a previous 
study, two-layer Coban2® was preferred to the four-layer Profore system (Moffat et al, 
2008), although pruritus was not assessed; bandage slippage was the key outcome measure 
in that study. In the present investigation the degree of bandage slippage was comparable 
between AndoFlex® TLC Calamine and Coban2® and less of an issue than itchiness, leg 
constriction and pain.  
The outcomes for wound size (PUSH), clinical severity of venous disease (VCSS), and 
vascular-related patient quality of life (CIVIQ20) were favourable for AndoFlex® TLC 
Calamine in this study, with significant differences found for the former two. However, this 
has to be placed in context of the study design and applicable inclusion and exclusion 
criteria. The crossover design means that both ‘Lite’ and full compression patients could be 
enrolled in the trial, since they were allocated the same compression strength for each of 
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the two bandage brands. Since the primary objective was to assess pruritus and other 
patient-reported symptoms associated with compression therapy, some non-ulcer patients 
were included in the trial too. An efficacy trial for wound healing and venous insufficiency 
symptomology is indicated to determine if improved patient-reported comfort levels  and 
indications of favourable healing associated with AndoFlex® TLC Calamine truly translate 
into a positive clinical response. Quantification of the wound size through wound tracing or 
digital measurement was not conducted for pragmatic reasons in this present study, but 
would have to be applied in a formal wound healing trial. Another limitation of the study 
includes a lack of blinding of participants and/or use of a blinded metrologist.  Furthermore, 
although patients were recruited from different sites, the majority of patients (92%) were 
recruited from a single site.  
This study has identified key patient-reported issues that may arise from wearing two-layer 
compression bandaging and this may aid clinical staff in clinics. Itchiness of the legs appears 
to be the biggest issue. The feeling of constriction, pain and movement restriction may 
occur in either AndoFlex® TLC Calamine or Coban2®, and one bandage may give better 
results than the other in those situations. Previous publications have previously reported 
that pain associated with having a leg ulcer is an issue, and that the degree of mobility 
whilst wearing compression bandaging is an important aspect considered by patients 
(Morgan et al, 2011; Walshe, 1995). Since in all patients but one, the compression 
bandaging was to be worn continuously, the impact of each bandage brand on therapy 
compliance rates was not assessed. However, compliance is a recognised issue.11  Since a 
possible reaction to AndoFlex® TLC Calamine was seen with one patient, a patch test with 
the base layer could be performed if there are any concerns regarding adverse reactions. 
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However, published cases of reactions to calamine are rare, and usually involve the 
presence or application of another substance (Gupta et al, 2007; Praditsuwan et al 1995). In 
the present study, related to tolerability, one patient who could only tolerate Coban2® for 
two days before having it changed could manage to wear an AndoFlex® TLC Calamine 
bandage for a consecutive four days.     
In conclusion, from a comfort perspective AndoFlex® TLC Calamine is preferred to Coban2® 
compression bandaging by patients. Pruritus levels appear low with AndoFlex® TLC 
Calamine, which supports the rationale of introducing Calamine to two-layer short stretch 
compression bandaging technology; however, the difference in pruritus levels as measured 
with validated outcome measures were non-significant compared to Coban2®. Further 
research is indicated to further explore the potential of AndoFlex® TLC Calamine to aid leg 
ulcer healing and wider clinical outcomes, through a non-crossover randomised controlled 
trial design, stratification by degree of compression (‘Lite’ and full compression), exclusion 
of non-ulcer patients, and a longer trial phase of – for example – 12 weeks. The putative 
contributory role of patient compliance with compression therapy should be explored too.  
 
Keywords: chronic venous insufficiency; compression bandaging; pruritus; venous leg ulcer; 
wound care 
Key points: 
• Compression bandaging of the lower legs, using a two-layer short stretch system like 
Coban2®, is a core treatment modality for patients with leg ulcers due to chronic 
venous insufficiency 
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• Minimising patient discomfort related to compression bandaging is important to 
reduce the risk of non-compliance with compression therapy 
• AndoFlex® TLC Calamine is a compression bandage system akin to Coban2® in terms 
of the degree of compression achieved; it does however, contain calamine in the 
skin-touching base layer. 
• In this cross-over trial, patients found AndoFlex® TLC Calamine more comfortable 
than Coban2® ; however, not to a significant degree when measured with validated 
pruritus scales. 
• Further research is indicated to investigate whether AndoFlex® TLC Calamine 
therapy can contribute to enhanced venous leg ulcer healing rates. 
Reflective questions: 
• Of the symptoms associated with two-layer compression therapy, evaluated through 
patient feedback in this study, which are the most common and most severe? 
• What aspects of compression therapy are important to patients and may contribute 
to improved compliance? 
• How may calamine impregnated bandage contribute to controlling undesirable 
symptoms associated with compression therapy? 
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Figure 1, CONSORT flowchart for APRICOT trial 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessed for eligibility: 61 
Analysed (n= 17) 
- Excluded from analysis (due to lack of data 
for both bandages) (n= 2) 
Lost to follow-up (n= 1, death) 
Withdrawn (n= 1, patient generally unwell and 
unwilling to wear any compression bandage) 
Received second bandage, AndoFlex® TLC 
Calamine (n = 17) 
 
Allocated to Coban2® first (n= 19; of which 
standard compression n= 3; Lite compression n= 
16) 
 
- Did not receive allocated intervention: not 
  
Lost to follow-up (n= 1, death) 
Withdrawn (n= 1, skin reaction to AndoFlex® TLC 
Calamine Lite) 
Received second bandage, Coban2® (n = 18) 
 
Allocated to AndoFlex® TLC Calamine first (n= 20; of 
which standard compression n= 8; Lite compression 
n= 12) 
- Did not receive allocated intervention: not 
applicable 
Analysed (n= 18) 
- Excluded from analysis (due to lack of data for 
both bandages) (n= 2) 
 
Randomisation 
Analysis 
Crossover to other bandage 
Excluded  (n= 22) 
-  Not meeting inclusion criteria 
(n= 22) 
-   Declined to participate (n= 0) 
-   Other reasons, LFU (n= 0) 
Enrollment 
Informed consent (n= 39) 
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Figure 2, Patient-reported occurrence frequency of symptoms associated with 
compression bandage therapy 
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Figure 3, Patient-reported severity of occurring symptoms (see Figure 2) associated with 
compression bandage therapy 
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Figure 4, Patient preference questionnaire at end of trial of both bandages (see Table 4 for 
description of questions Q1-Q9) 
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Table 1, Demographics and clinical parameters at baseline (trial completers only; normal 
and Lite compression patients combined) 
 Cohort  
Variable Coban2® first  
[n=17] 
AndoFlex® TLC 
Calamine first 
[n=18] 
Complete study 
population [n=35] 
Age in yrs, mean  (95% CI) 78 (74 to 82)  70 (63 to 77)  74 (69 to 78) 
Sex, male (%) / female (%), n  8 (47%) / 9 (53%)  9 (50%) / 9 (50%) 17 (49%) / 18 (51%) 
BMI in kg/m2, mean (95% CI) 
 
31 (27 to 35) 
[n= 16] 
32 (29 to 36) 
[n= 14] 
32 (29 to 34) 
[n=30] 
Smoking status, never / ex / current, n 9 / 4 / 1  
[n= 14] 
10 / 2 / 2  
[n= 14] 
19 / 6 /3 
[n= 28] 
Reason for compression bandaging, 
ulcer / post-surgery / conservative, n 
13 / 2 / 2  16 / 1 / 1 19 / 3 / 3 
Mobility status, w/o assist / w assist / 
unable to walk 
8 / 4 / 3 
[n=15] 
9 / 6 / 0 
[n=15] 
17 / 10 / 3 
[n =30] 
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Table 2, Measurement and comparison of outcome measures between Coban2® and AndoFlex® TLC Calamine 
 
Outcome 
measure 
Baseline, week 0 Week 3 (pre-crossover) Week 6 (post-crossover) Crossover analyses 
AndoFlex® 
first (n = 
18) 
Coban2®  
first 
(n=17) 
p-
value*  
AndoFlex®  
(n = 18) 
Coban2® 
(n = 17)    
p-
value*  
Coban2® 
(n = 18)    
AndoFlex®  
(n = 17) 
p-
value*  
Carryover 
effect, p-
value** 
Treatment 
effect, p-
value** 
Severity of 
Pruritus Score, 
median (IQR)  
0.5  
(0 to 1.3) 
1  
(0 to 2.5) 
0.30 0  
(0 to 1) 
1  
(0 to 2.5) 
0.10 0  
(0 to 1.3) 
1  
(0 to 1) 
0.26 0.10 0.24 
Visual pruritus 
scale, median 
(IQR) 
2  
(0 to 5) 
5  
(0 to 6) 
0.35 0  
(0 to 3) 
4  
(0 to 6) 
0.28 0  
(0 to 4) 
1  
(0 to 4) 
0.26 0.17 0.23 
5D itch score, 
median (IQR) 
8.5  
(5 to 12) 
10  
(5 to 14) 
0.38 5  
(5 to 9) 
7  
(5 to 12) 
0.18 5  
(5 to 9) 
7  
(5 to 10) 
0.20 0.12 0.36 
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PUSH, median 
(IQR)~ 
10  
(8 to 12.5)   
8  
(2.5 to 9)  
0.010 10  
(1 to 12.5) 
7.5  
(0 to 11) 
0.54 7  
(0 to 10) 
0  
(0 to 9) 
0.15 0.49 0.002 
VCSS, median 
(IQR)+  
13  
(10 to 17)  
12  
(11 to 17) 
0.61 11  
(7 to 16) 
11  
(8 to 13) 
0.97 11  
(5 to 14) 
8  
(5 to 12) 
0.39 0.64 <0.001 
CIVIQ20, 
median (IQR) 
54  
(31 to 74)  
61  
(46 to 67) 
0.61 44  
(25 to 61) 
49  
(29 to 54) 
0.59 43  
(23 to 54) 
38  
(29 to 54) 
0.90 0.88 0.055 
~ AndoFlex® n=17, Coban2® n=16; + AndoFlex® n=17, Coban2® n=17; *Mann-Whitney U-test; ** Wilcoxon signed-rank test; IQR, Interquartile 
range 
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Table 3, Patient preference survey questions asked at end of trial (results summarised in 
Figure 4). 
 
 
 
 
 
 
 
 
 
 
 
Question 
1. Overall, the bandage of my preferred choice is:  
2. I would recommend the following bandage to other patients: 
3. The bandage that was most comfortable to wear was: 
4. The bandage easiest to apply to my leg(s)  - or applied by someone else - was: 
5. The bandage that was easiest to move about in was: 
6. The bandage that allowed me to use normal footwear/shoes the best was:  
7. I had the least itchiness problems with: 
8. I had the best night rest when I was using the following bandage: 
9. The bandage that was the most comfortable for my skin was: 
